ArticleInflammopharmacology2025
Assessment of anti-arthritic potential of pulegone in formaldehyde- and Complete Freund's Adjuvant-induced arthritis in rats.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulegone, a monoterpene phytochemical, was evaluated for its anti-inflammatory and anti-arthritic properties. This study investigated its preventive efficacy against rheumatoid arthritis using in vivo animal models and in vitro assays. The in vitro analysis included the inhibition of egg albumin and bovine serum albumin (BSA) denaturation, as well as the stabilization of red blood cell membranes against hemolysis, across concentrations of 50-6400 μg/mL. For in vivo evaluation, arthritis was induced using formaldehyde and Complete Freund's Adjuvant (CFA) models, with pulegone administered at doses of 20, 40, and 80 mg/kg. The mRNA expression levels of key inflammatory mediators, including interleukin-1 beta (IL-1β), interleukin-17 (IL-17), nuclear factor-kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α), interleukin receptor-associated kinase (IRAK), and interleukin (IL)-10 and IL-17, were also analyzed. Results showed concentration-dependent inhibition of egg albumin and BSA denaturation, with maximum erythrocyte membrane-stabilizing effects observed at 6400 μg/mL. Pulegone exhibited dose-dependent anti-arthritic activity in the formaldehyde model, with the highest efficacy at 80 mg/kg. In the CFA model, pulegone significantly reduced arthritic lesions, mitigated weight loss, reversed hematological and biochemical abnormalities, and improved radiographic and histopathological outcomes. Additionally, pulegone demonstrated potent antioxidant effects in superoxide dismutase and reducing power assays. Treatment with pulegone significantly reduced pro-inflammatory cytokines (IL-1β, TNF-α, IRAK, and NF-κB) while increasing anti-inflammatory cytokines (IL-10 and IL-17) compared to the control group. In conclusion, pulegone effectively suppressed inflammatory responses in rheumatoid arthritis by modulating cytokine levels and enhancing antioxidant activity, making it a promising candidate for therapeutic development.
Indexed as
Identifiers
40676372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.